The Scientist - Home

therapy pool Here are a few of the recent deals: The Giant The Gene Therapy Co. The Deal Biogen Inc. Genovo Inc. Seed money: $38 million, 5 years Bristol-Myers Somatix Therapy Corp. Initial $10 million Squibb Co. stock purchase Ciba-Geigy Chiron Corp. 49.9% stake for Ltd. $2.1 billion Glaxo Sequana Therapeutics Undisclosed Wellcome Inc. Megabios Corp. milestone Spectra Biomedical Inc. payments Merck & Co. Vical Inc. $10.4 million Inc. invested to date Rh’ne-Poulenc 14 gene therapy firms

Vitality, Resilience Author: Catherine Didion EDITOR'S NOTE: In September Didion, executive director of the Association for Women in Science (AWIS), was among an AWIS delegation attending the United Nations Fourth World Conference on Women in Beijing, China, and the Non Governmental Organization Forum held in the small town of Huairou, an hour from Beijing. Noting that the torrential rain in Huairou -- the effects of which were exacerbated by the uncomfortable conference facilities -- and pa

In Science Author: Robert Finn Sidebar: PROPORTION OF FULL PROFESSORS AMONG FORMER POSTDOCTORAL FELLOWS IN ACADEMIC SCIENCE A recently released study from Harvard University examining the careers of scientists who showed high promise as postdocs has found persistent gender differences in career outcomes. The study, called Project Access, reveals clear evidence of a glass ceiling for women in certain fields, notes differences in publication patterns, and elucidates the way that family-related

Another Lasker Legacy Dedicated The Next Best Thing to Being There Turbine With A Twist Big Barbie and No-Neck Ken French Foundation Funding Renaissance Scientist NIGMS Web Site MacHome Page Brookhaven As Curator A GOOD NAME: The new biotech building honors biomedical activist Mary Lasker The late Mary Lasker, renowned for her devotion to the cause of advancing biomedical research, was honored with the dedication of a science-park building in her memory on November 2. New York City's first

Laboratories and Branches Director, Richard Klausner Deputy Director, Alan Rabson Legislative Liaison, Dorothy Tisevich Associate Director for Strategic Planning, Edward Sondik Office of Extramural Management Associate Director, Philip D. Amoruso Office of Intramural Management Associate Director, MaryAnn Guerra Office of Cancer Communications Associate Director, J. Paul Van Nevel International Cancer Information Center Associate Director, Susan Hubbard Office of International Affairs Associat

F. Sherwood Rowland - Chemistry Mario J. Molina - Chemistry Christiane Nüsslein-Volhard - Physiology or Medicine Frederick Reines - Physics Joseph Rotblat - Peace Paul Crutzen - Chemistry Martin L. Perl - Physics Eric F. Wieschaus - Physiology or Medicine

FELLOWS IN ACADEMIC SCIENCE MEN WOMEN Biology PSME* Social Biology PSME* Social Sciences Sciences Ph.D. Pre-1978: 0.57 0.70 0.83 0.43 0.37 0.50 N**=56 N=105 N=24 N=23 N=19 N=14 Ph.D. 1978 and After: 0.03 0.10 0.33 0.04 0.00 0.00 N=32 N=89 N=9 N=28 N=16 N=8 *Physical sciences, mathematics, and engineering ** Number of respondents (The Scientist, Vol:9, #22, pg.9 , November 13, 1995) (Copyright © The Scientist, Inc.)

Strategies Author: Karen Young Kreeger SIDEBAR: Significant Recent Biotech Product Approvals Amid a year of continuing hostile capital markets and product failures, biotech executives are retrenching, planning, and implementing scaled-down business plans they hope will sustain their industry into the next century. Their primary strategy to endure is to adopt tactics that are less reliant on public financing and the drug-approval process, according to the 10th annual Ernst and Young report on

Members Disperse Author: Billy Goodman Sidebar:Where Are Roche Institute Members Going? The Roche Institute of Molecular Biology (RIMB)-once one of the premier basic research labs in the United States-is about to go dark. Hoffmann-La Roche Inc., the Swiss-owned pharmaceutical giant that chartered RIMB and gave it a great deal of independence, decided a year ago to close the Nutley, N.J.-based institute and move it to Palo Alto, Calif., where the company had just bought Syntex Corp., a small bio

Departing Roche Institute members received severance packages from Hoffmann-La Roche that include bridging grants to help the researchers restart their labs and pay their postdocs, and they are allowed to take essentially all their laboratory equipment with them. This generous offer comes with strings attached, say institute scientists: They must agree not to speak negatively of Hoffmann-La Roche or its officers. If the dispersing scientists hold their tongues--and many would not speak on the

In 1967, the establishment of the Roche Institute of Molecular Biology (RIMB) by Hoffmann-La Roche received wide news coverage.

Clnical Medicine Research, 1990-94 VS 1981-85. (Ranked by the magnitude of change among those publishing 1,000 or more papers, 1990-94) Institution Percent Change University of Texas, San Antonio +78 Oregon Health Sciences University +74 State University of New York, Stony Brook +70 Louisiana State University +65 University of Nebraska +63 University of Miami +62 City University of New York +61 Loyola University +61 Tulane University +61 Wake Forest University +57 Northwestern University +55 Un